US 12,227,584 B2
Multivalent and multispecific OX40-binding fusion proteins
Brendan P. Eckelman, Encinitas, CA (US); John C. Timmer, San Diego, CA (US); Chelsie Macedo, La Jolla, CA (US); Kyle S. Jones, San Marcos, CA (US); Abrahim Hussain, La Jolla, CA (US); Amir S. Razai, La Jolla, CA (US); Bryan Becklund, San Diego, CA (US); Rajay Pandit, La Jolla, CA (US); Mike Kaplan, La Jolla, CA (US); Lucas Rascon, La Jolla, CA (US); and Quinn Deveraux, La Jolla, CA (US)
Assigned to Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed by Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed on Aug. 10, 2021, as Appl. No. 17/398,851.
Application 17/398,851 is a division of application No. 16/295,332, filed on Mar. 7, 2019, granted, now 11,117,972.
Application 16/295,332 is a division of application No. 15/404,167, filed on Jan. 11, 2017, abandoned.
Claims priority of provisional application 62/277,027, filed on Jan. 11, 2016.
Prior Publication US 2022/0106397 A1, Apr. 7, 2022
Int. Cl. A61K 39/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2878 (2013.01) [C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/569 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01)] 18 Claims
 
1. A method of treating cancer in a human subject having cancer comprising administering to the subject an isolated polypeptide that binds human OX40 and comprises at least one VHH that binds to OX40, wherein the at least one VHH that binds to OX40 comprises a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 36, a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 37, and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 42.